Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed. Of 305 charts reviewed, consisting of 279 unique patients, 27.2% were judged to have an indication for an LAI (n = 76), but only 32.9% of these (n = 25) were discharged on an LAI. In the multiregression model, being African American, residing in a psychiatric residence, having a previous history of an LAI trial, and being treated with a higher antipsychotic dose were predictive of LAI prescription. It is important to focus on the population who are not likely to receive an LAI, but who have such indications for treatment. Int Clin Psychopharmacol 32:161-168
Introduction
Nonadherence or poor adherence to taking medication is a universal problem in medical practice (Peterson et al., 2003; DiMatteo, 2004; Osterberg and Blaschke, 2005) . Nonadherence rates in patients with schizophrenia are known to be high in comparison with patients with other illnesses (Cramer and Rosenheck, 1998; Velligan et al., 2009) . Estimates in the literature range between 40 and 50%, but can be as high as 89% (Lacro et al., 2002) . Such high nonadherence rates in this population can limit the effectiveness of pharmacotherapy. Therefore, the use of long-acting injectable antipsychotics (LAIs) is considered to be an important treatment option (Kane and Garcia-Ribera, 2009; Barnes, 2011) . Current guidelines recommend LAIs when adherence is inadequate (Lehman et al., 2004; Canadian Psychiatric Association, 2005; Moore et al., 2007; NCCMH, 2010) . LAIs can not only ensure medication delivery among patients with poor adherence but also deal efficiently with covert nonadherence (Barnes and Curson, 1994) , prevent abrupt loss of effectiveness if a dose is missed, relieve patients from the burden of daily dosing, and enable care providers to be immediately aware of nonadherence (Kane and Garcia-Ribera, 2009; Barnes, 2011) . Moreover, it is reported that patients' attitudes toward LAIs are considerably more positive than is assumed by many clinicians (Wistedt, 1995; Pereira and Pinto, 1997; Walburn et al., 2001; Waddell and Taylor, 2009; Caroli et al., 2011) .
Despite these advantages, LAIs are grossly underutilized (Fayek et al., 2003) . In the USA, the prescription rate in schizophrenia has never increased above 12% and has been estimated to be less than 6% in the most recent decade (Fayek et al., 2003; Ahn et al., 2008) . Given the gap between the high nonadherence rate and the low LAI prescription rate, it is important to better understand the characteristics of patients who do and do not receive LAIs.
Factors related to LAI prescription have been studied previously. These include male sex, young age, an ethnic minority, more previous hospitalizations, living alone, more arrests in the past, alcohol and illicit substances use, nonadherence, previous use of an LAI, antipsychotic combination therapy, anticholinergic medication use, poor insight, more severe psychopathology, and disorganized thinking (Price et al., 1985; Covell et al., 2002; Kreyenbuhl et al., 2003; Arnold et al., 2004; Shi et al., 2007; Vehof et al., 2008; Aggarwal et al., 2012) . However, these reports are based on large prescription databases and generally compare patients on LAIs with patients on oral medications. Such data are not specifically focused on those patients for whom there are clear clinical indications for LAI use.
One major exception was a study carried out by West et al. (2008) , which surveyed over 500 psychiatrists. LAI prescription was associated positively with the patient having public insurance, previous inpatient admission, the proportion of time the patient was nonadherent, average or above average intellectual functioning, and living in a mental health residence, whereas it was found to be inversely associated with using second-generation antipsychotics and other oral psychotropic medications (antidepressant, mood stabilizers and anxiolytics/hypnotics) before medication nonadherence. Another somewhat similar study from South Korea (Kim et al., 2013) aimed to investigate the reasons for underuse of LAI and consisted of a survey of both psychiatrists and patients. Psychiatrists who were more familiar with LAI use were more likely to prescribe an LAI and their patients were more likely to have higher overall rates of satisfaction with the treatment compared with patient groups with psychiatrists who were less familiar with the treatment as they tended to recommend less and ultimately prescribe less. This is suggestive that there was a discrepancy between what some psychiatrists suspected in comparison with patients' actual beliefs about LAI treatment. Weaknesses of both studies include exclusive reliance on self-report and possible recall bias.
A better understanding of the pattern of LAI prescription may help to facilitate proper utilization in the future. We, therefore, examined consecutive (unselected) inpatient charts in which we established patients' history of adherence problems on the basis of their clinical record. This enabled us to explore the factors associated with LAI prescription among patients who had clear indications for LAI use.
Patients and methods

Materials
The study was carried out at The Zucker Hillside Hospital/Northwell Health, which is a 208-bed, private, not-for-profit psychiatric hospital located in a semiurban area of New York City and draws from a very large and diverse population. The electronic medical record system enabled us to select charts of consecutively admitted patients with specific diagnoses and review them electronically. We collected 400 charts of consecutive inpatient admissions with diagnoses of schizophrenia spectrum disorders, beginning 1 January 2010. As the aim of this study was to examine medical decision-making in terms of the utilization of LAIs, we excluded patients whose diagnoses were schizophreniform disorder, brief psychotic episode, psychotic disorder not otherwise specified, and whose primay diagnoses were nonschizophrenia spectrum. Moreover, although we acknowledge that the co-occurrence of developmental disability is one of the important characteristics of patients who are hospitalized multiple times, we excluded those patients, considering that the medical decisionmaking for such patients involves other factors. For similar reasons, we excluded patients with dementia. The study was approved by the Institutional Review Board of Northwell Health and was carried out in accordance with the ethical principles of the Declaration of Helsinki.
Chart review
Sociodemograhpic characteristics including age at the index hospitalization, sex, race/ethnicity, marital, domiciliary [whether patients live alone, with family, or in psychiatric residence (24-h staffed residences with supervised medication and skill training, apartments with staff visiting on regular and as needed basis, OR independent supported housing)], employment and insurance statuses, and criminal history were extracted from the charts. Diagnostic and therapeutic information including primary and secondary diagnoses, onset of illness, number of hospitalizations, medication history, alcohol use and illicit drug use in the preceding 3 months, lifetime drug abuse, duration of index hospitalization, and discharge medication was also extracted. Information on adherence was described on the basis of patients' and caregivers' reports. We stratified patients' adherence history into three categories: full adherence, meaning taking 100% or nearly 100% of the medication; nonadherence, meaning missing most of or all of the medication; and partial adherence, defined as intermediate between full and nonadherence, such that the patient missed a substantial proportion of the medication. Examples of the latter included taking doses on some, but not all days, receiving injections, but not taking prescribed oral medication concomitantly. Each hospitalization was categorized on the basis of these three adherence levels. We also attempted to determine the reasons for physician decision-making on the prescription of LAIs. Finally, with respect to postdischarge follow-up, we determined whether patients were readmitted within 3 months.
Indication for an long-acting injectable
None of the guidelines has clearly defined a recommended threshold for the initiation of LAIs. We therefore defined three such levels of indications to determine factors associated with LAI prescription. These three criteria are as follows:
(1) Strong LAI indication: index hospitalization because of nonadherence AND at least two previous hospitalizations because of nonadherence. We then calculated the proportion of admission cases that fulfilled these criteria and the proportion of admission cases that were discharged on LAIs to understand their utilization among patients for whom they are indicated with varying thresholds of rationale.
Sample size determination
The study sample was a convenience sample consisting of consecutively admitted inpatients with diagnoses of schizophrenia spectrum disorders, beginning 1 January 2010. As this was a descriptive, explorative study, we did not have a formal hypothesis to estimate the sample size. Hence, we used the '10 cases (charts) per variable' rule, which has been used to determine the sample size in descriptive chart review studies (Harrell et al., 1985; Findley and Daum, 1989; Sackett et al., 1991; Gearing et al., 2006) .
We had 20 predictor variables in the final regression equation. According to the above rule, 200 charts would have been an adequate sample. To ensure that we were not compromising the power of the study as well as taking into account the possibility of identifying additional meaningful variables during the chart review, we decided to target around 300 charts to be included in the analysis. Given the possibility that we would have to exclude charts because of missing data and other reasons, we believed that 400 charts would be an adequate sample size.
Statistical analysis
Sociodemographic and diagnostic characteristics of the patients who met the LAI indication were compared with those of the patients who did not fulfill the criteria. To avoid analyzing patients who had multiple admissions during the study period, we excluded subsequent admission data from these analyses. For these comparisons, we chose level 2 criteria over level 1 or 3 (see Fig. 1 for definitions) as it is conservative and yet clearly shows an indication for using an LAI. Next, we compared patients with the level 2 criteria who were discharged on an LAI with those who were not. Distributions of all variables were inspected using histograms, q-q plots, and Shapiro-Wilks tests before carrying out statistical analyses. Differences in patient characteristics between groups were examined using χ 2 -analysis for categorical variables and analysis of variance or the Wilcoxon rank sum test for continuous variables. To determine the best predictive model for LAI prescription, we carried out a multivariate logistic regression analysis with stepwise backward elimination model selection method. Only the variables that were different between the two groups at a significance level of less than 0.1 in Table 1 were considered as potential predictors in the model selection method. All analyses were two sided, with α set at 0.05, using JMP 5.0.1, SAS V9.2 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Patient demographics
A total of 400 charts starting from 1 January 2010 to 21 May 2010 were reviewed. Ninety-five charts were excluded from the analysis for the following reasons: comorbidity of developmental disability 44/95 (46.3%), likely primary diagnosis of mood disorder 22/95 (23.2%), likely primary diagnosis of psychotic disorder not otherwise specified 11/95 (11.6%), other principal diagnoses 15/95 (15.8%), and age younger than 18 years 3/95 (3.2%).
A total of 305 charts were used for the analysis. Twenty patients were admitted two times, three patients were admitted three times, and one patient each was admitted four, five, and six times during the study period. Thus, a total of 279 unique patients contributed to the 305 admitted patients reviewed. Demographic characteristics of the 279 patients are shown in Table 1 .
Adherence
The majority of charts provided information on adherence before the index hospitalization. Reasons for not prescribing an LAI were rarely described in the chart. The reasons provided were previous failed trial [n = 16, adverse events (n = 6), poor adherence
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Patient characteristics related to long-acting injectable indication and discharge on long-acting injectable Differences in the demographic and diagnostic characteristics between patients who had clear indications for an LAI versus those who did not are shown in Table 1 . Patients with indications for an LAI differed with respect to secondary diagnoses, were more likely to have substance/alcohol abuse or dependence, and have more frequent recent admissions compared with the patients without indications. We also found significant differences in race/ethnicity, residence, previous LAI trials, and chlorpromazine equivalent dose between patients who were discharged on an LAI and patients who were not discharged on an LAI despite indications (Table 1) .
Predictor for long-acting injectable prescription
On constructing a stepwise backward elimination multiple regression model, prescription of LAI was significantly associated with being African American [odds ratio (OR): 12.4, 95% confidence interval (CI): 2.9-52.9, P = 0.001], living in psychiatric residence before admission (OR: 5.2, 95% CI: 1.4-20.0, P = 0.016), and higher chlorpromazine equivalent dose (OR: 1.002, 95% CI: 1.0003-1.0044, P = 0.022) (r 2 = 0.503, P ≤ 0.001).
Readmission
Postdischarge data were available for 237 out of 305 admissions. Readmission within 3 months of discharge occurred in a total of 66 admission cases. Although patients discharged on LAI seemed less likely to be readmitted compared with patients not discharged on an LAI (19.5 vs. 29.6%), the difference did not reach statistical significance (P = 0.19)
Discussion
We performed a chart review to examine the impact of cliniclly determined and documented nonadherence on clinical practice and to explore factors associated with LAI prescription. Three major findings from the study should be emphasized.
First, we found that a large proportion of patients (58.4%) were admitted because of nonadherenece or partial adherence to treatment. Moreover, many of these patients had a previous history of hospitalizations related to nonadherance. Because of the nature of the study, adherence information was extracted from what was written during the course of routine clinical assessment, that is, information was provided by patient and/or caregiver report. It is known that the prevalence of nonadherence increases when more precise assessment methods are applied, for example, blood levels of prescribed medication. It is likely, therefore, that the very high nonadherence and poor-adherence rate found in our study using retrospective methods biased by selfreport is an underestimate of actual nonadherence rates. In addition, although LAIs have been shown to generally improve relapse prevention, recent research has shown that it is still possible with these agents despite adherence (Alphs et al., 2016) . Our results highlight the need for more detailed and accurate adherence assessment, especially when patients are experiencing relapse. An inaccurate assessment of adherence can lead psychiatrists to misinterpret patients' response or lack of response to medication. Physicians may increase the dose of medication because they believe that the current dose is not adequate for relapse prevention, when in fact the patient may actually not be taking the medication.
Excessive doses of medication increase the risk of adverse effects, potentially contributing further toward nonadherence.
Second, LAIs were prescribed in only 1/4 to 1/3 of patients who had clear indications for LAIs on the basis of our definition. Although major guidelines recommend the use of LAIs when there is a risk of nonadherence (Lehman et al., 2004; Moore et al., 2007; Buchanan et al., 2010; NCCMH, 2010) , no guidelines specifically state under what circumstances LAIs should be used. We, therefore, defined three categories ('strong,' 'moderately strong', and 'moderate') for the LAI indication and examined the prescription rate in each category. It is likely that the low prescription rate in our population reflects the general trend of LAI use in the USA compared with the relatively high LAI utilization rate in some other countries, for example, 21.5% in Belgium (Hanssens et al., 2006) , 23.3% in New Zealand (Humberstone et al., 2004) , 25% in Australia (Castle et al., 2002) , 29% in the UK (Paton et al., 2003) , and 75.0% in Singapore (Sim et al., 2004) . Like Korea (Kim et al., 2013) , the prescription rate in the USA is very low (Fayek et al., 2003) . If the prescription rate of LAI is to increase, it is important to have a greater understanding of the underlying factors related to clinical utilization.
Third, when we compared patients for whom an LAI was indicated with those for whom it was not, the former were more likely to have substance/alcohol abuse or dependence and have more recent admissions. These findings are consistent with previous reports (Shi et al., 2007) . When we compared patients who were discharged on an LAI with those who were not despite having a clear indication, patients discharged on an LAI were more likely to be African American, living in a psychiatric residence, have previous LAI trials, and receive higher antipsychotic doses and were less likely to be White. Of these factors, African American race, living in psychiatric residence, and receiving a higher antipsychotic dose remained significant factors associated with LAI prescription in the multivariate regression analysis. In our clinical setting, we speculate that these factors may be further associated with the ethnic make-up of patients residing in our local psychiatric residences, the oversight of residences that may include the administration of LAIs, and a proxy for severity of illness, that is, use of high-dose antipsychotic strategies. The findings ultimately contribute toward our knowledge base with respect to which factors are associated with LAI prescription in clinical practice. We should also emphasize that those patients who did not have those characteristics were less likely to receive LAIs even though they might derive significant benefit from them. Psychiatrists may overlook the potential benefit of starting LAIs for such patients. In addition, there may be other factors that contribute toward the underprescribing of LAIs such as LAI availability on prescription drug formularies, cost, a facility's ability to administer, and patients' willingness to accept that we could not explore by means of chart review. Although we have identified several factors that were related to the prescription of LAIs in our cohort, it is also important to understand why the prescription rate is low in general. Previous research has suggested reasons for LAI underutilization listed as follows: the doctors' belief of increased adverse events (Kissling, 1994; Kane et al., 1998) , doctors' belief of negative attitudes of patients, stigma or negative image problem (Glazer and Kane, 1992; Heres et al., 2006; Waddell and Taylor, 2009; Heres et al., 2011) , lack of prescribing knowledge and experience (Dencker and Axelsson, 1996) , restrictive evidence (Kishimoto et al., 2014), etc. Presumably, such factors combined with individual patient characteristics affect prescribers' decision-making. However, although such information about reasons for LAI underutilization is useful, it does not provide a clear picture of the direct/ indirect factors involved in each decision-making process.
To establish strategies to facilitate the appropriate use of LAIs in the future, we need to collect information from prescribers as to when and why they prescribe LAIs and why they do not, even when indicated on the basis of the actual patient's case.
The results of the study need to be interpreted in the context of several limitations. Because of the study design, the information was limited to the narrative data available in the medical records. With respect to obtaining information on the role of adherence before hospitalization, although we had relatively detailed information when the patients had been admitted to our hospital, it was not possible to obtain as accurate information in instances of hospitalization elsewhere. The lack of information on past admissions, however, is likely to have resulted in an underestimate of the true adherence rate. Therefore, one of our findings, that is, the low LAI prescription rate for patients who have indications for LAI treatment, was likely biased in a conservative direction. Another important limitation of our study is the lack of information on psychopathology. Factors such as poor insight likely influence the decision to accept and prescribe LAIs. The proxy for the severity of psychopathology or relative treatment refractoriness in our analysis was chlorpromazine equivalent dose. We found that patients on higher doses were more likely to receive LAIs. However, the correlation of antipsychotic dose and the severity of psychopathology is unknown in our study. We could not adequately capture and study patients' admission legal status, legal status at the time of initiation of LAI, whether or not treatment was court ordered, and the relationship of these factors with the outcome of a patient receiving LAI. We found that in many charts, some fundamental information, for example, medication trial history such as dose, duration, response and adherence, or why/why not LAI was prescribed was not documented. Therefore, to make the best decisions for patients, this information is crucial and it is a significant impediment to optimal patient outcome. Documentation of detailed medication history should be a high priority for the field as a whole. Clinicians may want to consider regular administration of an adherence instrument such as the Brief Adherence Rating Scale. This scale is a pencil-and-paper, clinician-administered instrument used to assess adherence to oral antipsychotic medication in outpatients with schizophrenia and schizoaffective disorder. Results using this scale compare favorably to electronic monitoring (Byerly et al., 2008) .
Conclusion
We found that the majority of patients with schizophrenia and schizoaffective disorder admitted to our hospital had adherence-related problems. LAI prescription overall was underutilized when indicated on the basis of our criteria. Predictors for LAI prescription were African American race, living in a psychiatric residence, and higher dose of medication. It is important to focus on the patients who are less likely to receive an LAI as they may derive considerable benefit from them. Future studies need to collect information from prescribers as to when they prescribe LAIs and the reasons why they do not, even when indicated.
